Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

Inclusion Criteria: 1. 28-75 years of age 2. Diagnosed with Type 2 Diabetes and evidence of preserved insulin secretion. Fasting insulin \> 7 μU/ mL. 3. Glycated Hemoglobin (HbA1c) of 7.5 - 10.0% (59-86 mmol/mol) 4. Body Mass Index (BMI) ≥ 24 and ≤ 40 kg/m2 5. Currently taking one or more oral glucose lowering medications of which one must be Metformin, with no changes in dose or medication in the previous 12 Weeks prior to study entry 6. Able to comply with study requirements and understand and sign the informed consent Exclusion Criteria: 1. Diagnosed with Type 1 Diabetes or with a history of ketoacidosis 2. Current use of Insulin 3. Current use of Glucagon-like peptide-1 (GLP-1) analogues 4. Hypoglycemia unawareness or a history of severe hypoglycemia (more than 1 severe hypoglycemic event, as defined by need for third-party-assistance, in the last year) 5. Known autoimmune disease, as evidenced by a positive Anti- Glutamic Acid Decarboxylase (GAD) test, including Celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder 6. Active H. pylori infection (Participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.) 7. Previous GI surgery that could affect the ability to treat the duodenum such as subjects who have had a Bilroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions 8. History of chronic or acute pancreatitis 9. Known active hepatitis or active liver disease 10. Symptomatic gallstones or kidney stones, acute cholecystitis or history of duodenal inflammatory diseases including Crohn's Disease and Celiac Disease 11. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia 12. Use of anticoagulation therapy (such as warfarin) which cannot be discontinued for 7 days before and 14 days after the procedure 13. Use of P2Y12 inhibitors (clopidogrel, pasugrel, ticagrelor) which cannot be discontinued for 14 days before and 14 days after the procedure. Use of aspirin is allowed. 14. Unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during treatment through 4 weeks post procedure phase 15. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide) 16. Receiving weight loss medications such as Meridia, Xenical, or over the counter weight loss medications 17. Persistent Anemia, defined as Hgb\<10 g/dl 18. Estimated Glomerular Filtration Rate (eGFR) or Modified of Diet in Renal Diseae (MDRD) \<30 ml/min/1.73m\^2 19. Active systemic infection 20. Active malignancy within the last 5 years 21. Not potential candidates for surgery or general anesthesia 22. Active illicit substance abuse or alcoholism 23. Participating in another ongoing clinical trial of an investigational drug or device 24. Any other mental or physical condition which, in the opinion of the Investigator, makes the subject a poor candidate for clinical trial participation